anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present invention relates to equine fetal tissue-derived stem cells, and a cell therapeutic agent for regenerating a musculoskeletal system, comprising same, and, more particularly, to: a method for preparing equine amniotic fluid-derived stem cells; the analysis of characteristics of amniotic fluid stem cells prepared by the method; equine amniotic fluid-derived stem cells comprising the stem cells as an active ingredient; and a cell therapeutic agent for regenerating a musculoskeletal system, comprising same. The present invention provides equine amniotic fluid-derived stem cells. In addition, the present invention provides a method for preparing equine amniotic fluid-derived mesenchymal stem cells, comprising the steps of: (step 1) collecting amniotic fluid from a pregnant horse; (step 2) isolating monocytes from the collected amniotic fluid; and (step 3) initially culturing the isolated amniotic fluid-derived monocytes. Moreover, the present invention provides a method for preparing equine mesenchymal stem cells, comprising the steps of: (step 1) collecting amniotic fluid from a pregnant horse; (step 2) isolating monocytes from the collected amniotic fluid; (step 3) initially culturing the isolated amniotic fluid-derived monocytes; (step 4) culturing the initially cultured equine amniotic fluid-derived cells of passages 3 to 5 by using the culture medium Dulbecco&#39;s Modified Eagle Medium (DMEM), which contains 10-20% fetal bovine serum (FBS), 0.5-1.5% glutamax, and 0.5-1.5% penicillin/streptomycin; and (step 5) removing the medium in a culture dish, washing same with phosphate buffered saline (PBS, pH 7.2), and then separating cells from the basal surface by using 0.01-0.1% Typsin-EDTA. The present invention also provides equine amniotic fluid-derived stem cells having a musculoskeletal system treatment function. Furthermore, the present invention provides a cell therapeutic agent for regenerating a musculoskeletal system, comprising the equine amniotic fluid-derived stem cells.
PURPOSE:To obtain a bacterium-derived hypotensor having low side effects, readily usable, containing an extract of a cell of lactic acid bacillus with water as an active ingredient. CONSTITUTION:A cell of lactic acid bacillus (e.g. Lactobacillus casei, L. plantarum, etc.) is suspended in water at &gt;=50 deg.C in 10-80mg/ml and extracted under a preferable condition for 10-60min. After the extraction is over, the cell, an insoluble substance comprising fragments thereof, etc., are removed to give an extracted solution, which is concentrated as it is and dried to give a hypotensor. Salts and other low-molecular weight substances are removed to give the more effective hypotensor (main components are 37% saccharide, 15% protein and 32% nucleic acid; yield is 10mg based on 100mg dried cell). The hypotensor can be readily made into any dosage form and can be administered orally (including sublingual administration) or parenterally (intravenous injection, intravenous drip, etc.).
PURPOSE:To obtain an aromatic composition capable of exhibiting extremely excellent retaining effect on fragrance having relatively high volatility and simultaneously suitable for practicality without giving tackiness even in blending with perfume or a fragrance product such as cologne. CONSTITUTION:The aromatic composition is obtained by blending a chain or cyclic dimethylpolysiloxane of formula I or formula II whose vapor pressure at 100 deg.C is 0.1-300mgHg, preferably 0.1-15mgHg, used as a retaining ingredient with an aromatic component in an amount of &gt;=10 pts.wt. preferably &gt;=100 pts.wt. based on 100 pts.wt. aromatic component. The dimethylpolysiloxane is suitable for practicality, because the compound is readily dissolved in a fragrance product system such as perfume and cologne and stably exists and simultaneously can be used for various purposes because the compound has good feeling of use and is almost odorless even when blended with these fragrance products and the retaining effect of the perfume having high volatility can long be expected.
PURPOSE:To provide the subject derivative comprising an adenosine derivative having a specific structure, having an adenosine deaminase-inhibiting action, and useful for agents for preventing and treating ischemic heart diseases, cerebrovasculare diseases, renal diseases, inflammatory allergic diseases, etc. CONSTITUTION:6-Chloro-9-(3,5-O-tetraisopropylsiloxane)-beta-D-ribofura nosyl-9H- purine is dissolved in ethyl iodide, mixed with silver oxide, simultaneously heated with stirring, and subsequently added to a silica gel column. The silica gel is washed with benzene, and subsequently eluted with ethyl acetate/hexane. The filtrate is vacuum-dried, and the residue is dissolved in benzene, mixed with a 40% aqueous solution, of monoamine stirred over a night, and subsequently separated into the benzene layer. The benzene layer is washed with 1N hydrochloric acid and then with aqueous solution, of a saturated salt mixed with a 1M tetra-n-butyl ammonium fluoride/THF solution, stirred at room temperature for 30min, and subsequently subjected to the vacuum distillation of the solvent. The residue is purified with a silica gel column to provide the objective compound (salt) of the formula (R is &gt;=2C alkyl).
1. A fast-acting analgesic drug form comprising as analgesic substance ibuprofen in an adjuvant matrix, having a porous structure and a density of greater than 1 and up to 2.5 g/cm&lt;3&gt;. 2. An analgesic as claimed in Claim 1, having a density of from 1.4 to 1.9 g/cm&lt;3&gt;. 3. An analgesic as claimed in Claim 1 or 2, comprising as matrix adjuvant at least one melt-processable polymeric binder. 4. An analgesic as claimed in Claim 3, comprising as polymeric binder a homo- or copolymer of N-vinylpyrrolidone. 5. An analgesic as claimed in Claims 1 to 4, obtainable by application of shear forces and extrusion of a mixture of ibuprofen and the matrix adjuvants. 6. An analgesic as claimed in any of Claims 1 to 6, obtainable by use of alkali metal or alkaline earth metal carbonates as matrix adjuvants. 7. An analgesic as claimed in one of Claims 1 to 6, comprising ibuprofen as racemate. 8. A process for producing an analgesic as claimed in Claim 1 to 7, by mixing the analgesic substance with the matrix adjuvants with application of shear forces and extrusion through a die with subsequent shaping, wherein the plasticized mixture is exposed to a vacuum before extrusion through the die.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a bicalutamide-containing formulation which is a formulation containing a bicalutamide being an anti-androgenically active compound and being a medicine widely used in the treatment of prostate cancer, using an additive lower in cost and higher in safety than conventional one, and being excellent in solubility.  &lt;P&gt;SOLUTION: The formulation is prepared by adding hydroxypropylcellulose to bicalutamide, as an active ingredient, represented by formula (1). It is preferable that the hydroxypropylcellulose added is in the range of 0.1-30 pts.wt. per 100 pts.wt. bicalutamide.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The present invention relates to recombinant Glut1 adeno-associated viral vector (rAAV) constructs and related methods for restoring Glut1 expression in Glut1 deficient mammals. In certain embodiments, the rAAV further comprises a chicken ß-actin promoter wherein the rAAV is capable of crossing the blood-brain barrier (BBB). In certain embodiments, the present invention relates to a composition comprising any of the recombinant AAV&#39;s described herein. In certain embodiments, the present invention relates to a kit comprising a container housing comprising the composition described herein. In certain embodiments, the present invention relates to methods of restoring Glut1 transport in the BBB of a subject, comprising administering to the subject an effective amount of any of the recombinant AAV vectors described herein. In certain embodiments, the present invention relates to a method of treating Glut1 deficiency syndrome in a subject in need thereof.
A compound of formula (I), or a salt, ester or other derivative thereof, wherein: A is a pyrrole ring. R1 is optionally substituted aryl or optionally substituted heteroaryl. R2 is optionally substituted heteroaryl having at least one nitrogen atom. R3 represents the group -X-R4, wherein: X is a single bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene. R4 is substituted cycloalkyl, substituted aryl, optionally substituted heteroaryl or a group of formula -NRaRb. The variables Ra, Rb, aryl, heteroaryl, alkylene, alkenylene, alkynylene, cycloalkyl and all substituents are as defined in the specification. Provided that in the compound of formula (I), the substituents R1 and R3 are bonded to the two atoms of the pyrrole ring which are adjacent to the atom on the pyrrole ring to which the R2 substituent is bonded.  Also described is a pharmaceutical composition that comprises the compound of formula (I) together with a carrier or diluent. The compounds of formula (I) can be used for the treatment or prophylaxis of diseases that can be treated or prevented by inhibiting the production of inflammatory cytokines in a mammal. The compounds of formula (I) can be used for: inhibiting bone resorption, treatment or prophylaxis of inflammatory diseases, treatment or prophylaxis of viral diseases, relief of pain or pyrexia, or for the treatment or prophylaxis of: arthritis, cancer, hepatitis, allergic diseases, septicaemia, psoriasis, osteoporosis, ulcerative colitis, diabetes, nephritis, ischemic heart disease, Alzheimer&#39;s disease and arteriosclerosis.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide iron oxide which has excellent dispersibility and is suitable for electronic component applications, pigment applications, cosmetic applications or the like, and to provide a method of manufacturing the same.  &lt;P&gt;SOLUTION: The iron oxide is flocculation particles of primary particles having diameters of ≤0.10 μm and has a median diameter of ≤0.60 μm. The iron oxide has such a particle diameter distribution that the difference between the flocculation particle diameter at the point where the accumulation of flocculation particles having larger particle size attains 10% and the median diameter of the flocculation particles is not higher than two times of the median diameter of the flocculation particles. Further, the iron oxide is manufactured by controlling the particle diameter of the iron oxide before being crushed so as to obtain volume ratios mentioned below and thereafter, crushing the iron oxide with an air flow-type crusher. The particle diameter control of the iron oxide before being crushed is performed so that the volume ratios of the particles having diameters of ≥1,000 μm, 1,000-106 μm, and &lt;106 μm become 5-25%, 35-75%, and ≤40%, respectively.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
PURPOSE: To impart curls with continuity and soft and smooth cosmetic characteristics to a person&#39;s hair treated with silicones by using steam under a specific condition. CONSTITUTION: First, a composition made of silicone derivatives is applied to a person&#39;s hair. This treatment with silicones can be given before, during, or after stretching of a bundle of hairs to make a finally requested hair style. Next, the bundle of hairs soaked with the silicones is kept in contact with gas including steam of at least 75 deg.C for a period not exceeding 2 minutes, and next, air is made to flow all through the bundles of hairs speedily at the room temperature, and/or the curled hair is sucked and cooled by air flow. Finally, a mechanical means, which keeps stretching of the bundles of hairs totally treated and set as a requested style, is removed from the hair. In this way, attractive and soft curls can be obtained.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cosmetic sheet sufficiently closely adhering to skin when removing keratotic plugs from the skin and having an excellent ability to remove the keratotic plugs from the skin.  &lt;P&gt;SOLUTION: The cosmetic sheet is a cosmetic sheet having short sides and long sides. One long side has two recessed part sides so as to be linear symmetry and linear cuts are provided in a truncated chevron shape between the recessed side and the short sides. The cosmetic sheet has a skin application layer and a moisture-permeating substrate on one surface of a separator. The skin application layer is preferably composed of a wet pressure-sensitive adhesive composition containing a water-soluble polymer and an inorganic filler.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PURPOSE:In a toothpaste composition containing powdery base to elute &gt;= bivalent metallic ion, the titled composition having improved shape retention and dispersibility in the mouth, causing no solid-liquid separation for a long period, using both a polyacrylic acid of crosslinking type and xanthan gum as a binder. CONSTITUTION:A toothpaste composition containing powdery base such as potassium secondary phosphate, etc. to elute &gt;= bivalent metallic ion as a brushing agent is blended with a polyacrylic acid of crosslinking type and/or its salt and xanthan gum. For example, Carbopol 940, Reogik 250H, etc. may be cited as the polyacrylic acid of crosslinking type or its salt. Especially the acrylic acid of crosslinking type or its salt having 10,000-80,000cps viscosity of 1wt% aqueous solution is preferable. A blending ratio of the polyacrylic acid of crosslinking type to xanthan gum is preferably 3:1-1:3 by weight, and total blended amounts of the two components are preferably 0.5-2.5wt% based on the total amounts of the composition.
NEW MATERIAL:A compound shown by formula I [R is H or hydrocarbon group which may contain substituent group; Ar is aromatic group; X is O or S; l is 0 or 1; m is 3-6; n is 0-2; ring A and Ar may contain substituent group, respectively] or a salt thereof. EXAMPLE:N-(2-Chlorobenzyl)-N&#39;-(2,4-difluorophenyl)-N-(2-indanyl)urea. USE:A drug. An acyl-CoA: cholesterol acyltransferase inhibitor. Having both weak acute toxicity and toxicity by continuous administration and effective for preventing and treating diseases such as hypercholesterolemia, atherosclerosis, etc. PREPARATION:A compound shown by formula II or a salt thereof is reacted with a compound shown by formula III in an inert solvent such as dichloroethane in the presence of a base such as triethylamine at -10 to 150 deg.C for 5 minutes to 24 hours to give a compound shown by formula I.
&lt;P&gt;PROBLEM TO BE SOLVED: To edit medical record information consisting of a plurality of entry items for an easy understanding.  &lt;P&gt;SOLUTION: A patient information storage means 11 stores order information containing character information representing a treatment for a patient, in association with patient identification information identifying the patient. An extraction means 12 extracts words specifying the treatment from the character information contained in the order information stored in the patient information storage means 11. An edit means 13 applies the words extracted by the extraction means 12 to a predetermined template to generate edit information. An edit information storage means 14 adds the edit information generated by the edit means 13 to the order information for storage in a storage means 15. An output means 16 outputs display information for displaying the edit information stored in the storage means 15 in response to a request to display the order information.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:The titled cosmetic containing powder constituting the pressed powdery cosmetic constituted of a spherical powder having a specific particle diameter in combination with a fine particulate powder, having a constant and uniform pressed hardness and improved removability and adhesion in use without causing the cracking of the pressed surface. CONSTITUTION:A pressed powdery cosmetic obtained from 20-90wt% based on powder constituting the pressed powdery cosmetic spherical powder having 1- 40mu, preferably 5-20mu particle diameter, e.g. inorganic powder such as calcium silicate, organic powder such as regenerated cellulose or homopolymer or copolymer powder or nylon powder, and 5-30wt% fine particulate powder having &lt;=0.1mu particle diameter, e.g. fine powder silica such as silicic acid anhydride or magnesium metasilicate aluminate. EFFECT:The spherical powder can be incorporated in a high proportion by the combination with the fine particles, and good pressability can be maintained. Usually used other components can be used in the same way as before.
The invention discloses a compound microcapsule preparation containing cartilage cells of epiphyseal plate or other cartilage cells. The compound microcapsule preparation comprises fresh cartilage cells of epiphyseal plate or immortalised cartilage cells of epiphyseal plate or other cartilage cells, a mixed carrier alginate-collagen-polylysine, a liquefying agent sodium citrate, and a curing agent calcium chloride. The number of the fresh cartilage cells of epiphyseal plate or the immortalised cartilage cells of epiphyseal plate (or other cartilage cells) is between 2*10&lt;6&gt; and 8*10&lt;6&gt;. The mixed carrier alginate-collagen-polylysine comprises the following components of 50-600 parts of alginate by weight, 10-100 parts of collagen by weight and 1-10 parts of polylysine by weight. The content of the liquefying agent sodium citrate is 2-20 parts by weight and the content of the curing agent calcium chloride is 1-10 parts by weight. The carrier material of the compound microcapsule preparation in the invention is a natural extract, has excellent biocompatibility, relatively strong mechanical strength and few side effects, and is suitable for treatment of early closure of epiphyseal injury.
The object of the invention is a measurement device and a system for measuring and monitoring information which relates to diabetes care. The purpose of the invention is to motivate a user to perform activities that are required in the care. In a preferred embodiment of the invention a performance levels are determined and the level of a user is based on the activities and/or measurement results of the user. Upon increase in the user&#39;s level the user is awarded with e.g. new reminder figure in the device. The motivation of a user to follow care activities is thus increased.
PROBLEM TO BE SOLVED: To obtain a peripheral vasodilator having telangiectatic action and high safety and useful for treatment, prophylaxis, etc., of shoulder stiffness, frostbite and alopecia by subjecting water extract of glycyrrhiza to lactic acid fermentation until pH value of water extract of glycyrrhiza becomes a specific value or below. SOLUTION: This peripheral vasodilator comprises a fermentation solution obtained by subjecting a water-extracted solution of glycyrrhiza to lactic acid fermentation until pH value of water extraction of glycyrrhiza becomes &lt;=5. It is preferable that the fermentation solution or its dehydration treated material contains liquilitin and lactic acid in an amount of 1-300 pts.wt. and glycyrrhizin in an amount of 1/30 to 3.9 pts.wt. based on 1 pt.wt. liquilitin and exhibits ultraviolet ray absorption at 265 to 275nm and 305-320nm and produces white precipitate when methanol, ethanol or acetone is added to an aqueous solution having 5g/100ml solid content and has no sweetness and subjected to sterilization treatment after fermentation.  Lactic acid fermentation is preferably carried out under facultative anaerobic conditions at 1-40 deg.C by using a lactic acid bacterium of the genus Lactobacillus or the genus Bifidobacterium.
The invention relates to an externally applied medicinal solution for treating hyperosteogeny, cervical spondylosis and lumbar disc herniation. The externally applied medicinal solution comprises the following medicinal materials: 10-20g of angelica sinensis, 10-20g of peach seeds, 10-20g of safflower, 10-20g of frankincense, 10-20g of myrrh, 10-20g of suberect spatholobus stem, 10-20g of clematis root, 10-20g of dragon&#39;s blood and 500g of vegetable oil. A preparation method comprises the following steps: adding 500g of vegetable oil into a stainless steel pan, boiling the oil to 150 degrees, firstly adding angelica sinensis, peach seeds, safflower, clematis root and suberect spatholobus stem into the pan, boiling with slow fire for 30min, then adding crushed frankincense and myrrh, frying for 10min, cooling until the temperature of the oil is 60 degrees, then adding ground dragon&#39;s blood into the medicinal oil, uniformly stirring, removing residues and bottling. The crushed and ground medicines in the formula do not need to be screened. A medium of the externally applied medicinal solution provided by the invention has good soaking property, the medicines can directly achieve an affected part to play the roles to a greatest extent, and the purpose of &#39;relieving pain by dredging&#39; is achieved. The externally applied medicinal solution provided by the method disclosed by the invention has no pain, no side effects, short single treatment time, sufficient medicinal source, no need of oral administration of the medicines and reliable curative effect, is easy to be accepted by a patient, is environment-friendly and is suitable for popularization and application.
The present invention relates to an application of glycine in medicine preparation. The glycine in medicine preparation can obviously reduce an enterogenous endotoxin level of plasma. Thus, the secretion of cytokines TNFa and IL-6 is reduced, the activity of plasma transaminase is obviously reduced, hepatic injury is obviously lightened and liver functions are obviously improved. By molecular biology method research at home and abroad, the glycine can obviously regulate down hepatic tissue LBP (lipopolysaccharide binding protein) mRNA, CD14 (endotoxin acceptor) genes and albuminous expression. By experimental confirmation, the glycine is the retarder of a mononuclear macrophage (such as kupffer cells and liver sinusoidal endothelial cells in the liver) film endotoxin acceptor (CD14). Thus, a signal transduction system in cells is blocked, and the biological effect of endotoxin is difficultly exerted. By clinical observation, the glycine can obviously reduce hepatopaths&#39; plasma endotoxin levels; simultaneously, the liver functions are obviously improved. The glycine is an effective drug for patients with various kinds of hepatitis, fatty liver, liver cirrhosis and shocks, and has no any adverse reaction.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a dietary supplement for reducing cellular damages within human bodies, in particular, to provide a method for producing a dietary supplement for removing in-vivo cortex hydroperoxide and super-oxide anion-free radicals.  &lt;P&gt;SOLUTION: Fruits of Morinda citrifolia are cropped and aged for zero to fourteen days and the aged fruits are stored in a plastic container for zero to thirty days. Then, the seeds and peels are separated mechanically from the fruit juice and flesh. The juice and flesh are filtered with a centrifugal decanter having a filter of 1 to 2,000 μm mesh screen, thus obtaining the fruit juice of Morinda citrifolia. The dietary supplement is produced by mixing the obtained juice with other ingredients.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an effective growth-promoting agent.  &lt;P&gt;SOLUTION: This growth-promoting agent which provides a substitute for fetal bovine serum is obtained from a milk product. Furthermore, a milk product extract composition comprises a plurality of cell growth promoting factors extracted from the milk product in a concentrated form and having a basic or a nearly neutral isoelectric point. A pharmaceutically or a veterinary composition comprises a cell culture composition and the milk product extract. A method for preparing the composition and a method for using the composition are provided.  &lt;P&gt;COPYRIGHT: (C)2003,JPO